Linagliptina/Metformina Stada

Active Ingredient:: Metformin Hydrochloride, Linagliptin
Origin:: EU

Linagliptina/Metformina Stada (Metformin Hydrochloride, Linagliptin)

Q: What is Linagliptina/Metformina Stada used for?

Linagliptina/Metformina Stada is a prescription oral medication used to improve blood glucose control in adults with type 2 diabetes mellitus, typically when diet, exercise, and monotherapy are insufficient.

Q: How does linagliptin work in this combination?

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which increases the levels of incretin hormones. This enhances glucose‑dependent insulin secretion and reduces glucagon release, helping lower blood sugar after meals.

Q: What is the usual dose of Linagliptina/Metformina Stada?

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Q: Is Linagliptina/Metformina safe during pregnancy or breastfeeding?

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

Q: How do I order Linagliptina/Metformina Stada from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Q: How does this product compare with other antidiabetic options?

Linagliptina/Metformina combines a DPP‑4 inhibitor with metformin, offering dual mechanisms of action. Compared with metformin alone, it provides additional post‑prandial glucose control, and unlike sulfonylureas, it carries a lower risk of hypoglycaemia when used as monotherapy.

Q: What are the storage requirements for Linagliptina/Metformina Stada?

The tablets should be stored at room temperature, below 25 °C, in the original blister pack or container, protected from moisture and direct sunlight to maintain stability.

Q: How is Linagliptina/Metformina administered?

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed.

Q: What are the most serious risks associated with this medication?

Serious risks include lactic acidosis (especially in patients with renal impairment), pancreatitis, severe allergic reactions, and acute kidney injury. Patients should be educated to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or signs of severe hypersensitivity.

Q: Who should not use Linagliptina/Metformina Stada?

The drug is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease.

Linagliptin/Metformin, the active ingredients in Linagliptina/Metformina Stada, are a combination of a DPP‑4 inhibitor and a biguanide presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adult patients who need additional glycaemic control beyond diet and exercise.

GNH India supplies Linagliptina/Metformina Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Laboratorio Stada, S.L.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Linagliptina/Metformina is indicated for the management of type 2 diabetes mellitus, acting on glucose metabolism pathways.

Type 2 diabetes mellitus: improves overall glycaemic control when used with diet and exercise.
Inadequate control on metformin alone: provides additional glucose‑lowering effect as part of combination therapy.
Metformin intolerance: offers an alternative DPP‑4 inhibitor component for patients who cannot tolerate high‑dose metformin.

How It Works

Linagliptin selectively inhibits dipeptidyl peptidase‑4 (DPP‑4), preventing degradation of endogenous incretin hormones and thereby enhancing glucose‑dependent insulin secretion. Metformin hydrochloride reduces hepatic gluconeogenesis, increases peripheral insulin sensitivity, and decreases intestinal glucose absorption, together producing a complementary reduction in blood glucose levels.

Side Effects

The following adverse reactions have been reported with the combination of linagliptin and metformin.

Common Side Effects

Nausea: mild to moderate gastrointestinal upset.
Diarrhoea: loose stools, often transient.
Headache: mild tension‑type headaches.
Dizziness: occasional light‑headedness.
Hypoglycaemia (when combined with sulfonylureas or insulin): low blood sugar episodes.
Abdominal discomfort: bloating or cramping.

Serious or Rare Side Effects

Lactic acidosis: rare but life‑threatening metabolic disturbance.
Pancreatitis: severe abdominal pain with elevated enzymes.
Severe allergic reactions: rash, angioedema, or anaphylaxis.
Hepatic failure: signs of liver dysfunction.
Acute kidney injury: reduced renal function.
Severe hypoglycaemia: especially in patients with renal impairment.

Precautions & Warnings

Before initiating therapy, clinicians should consider several safety aspects.

Renal function monitoring: assess eGFR and adjust dose if needed.
Hepatic function monitoring: evaluate liver enzymes periodically.
Contraindicated in severe renal impairment: avoid use when eGFR <30 mL/min/1.73 m².
Use with caution in heart failure: monitor for fluid overload.
Pregnancy and breastfeeding: only if benefits outweigh potential risks.
Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Avoid Interactions

Linagliptina/Metformina may interact with other medicines; interactions are grouped by clinical relevance.

Major Interactions (Avoid)

Iodinated contrast agents: can precipitate acute renal failure with metformin.
Cimetidine: may increase metformin plasma concentrations.
Trimethoprim: can raise metformin levels and risk lactic acidosis.
Strong CYP3A4 inhibitors: may affect linagliptin exposure.
Alcohol excess: enhances risk of lactic acidosis.

Moderate Interactions (Monitor Closely)

ACE inhibitors or ARBs: monitor renal function and potassium.
Diuretics: may affect fluid and electrolyte balance.
NSAIDs: increase risk of renal impairment.
Beta‑blockers: may mask hypoglycaemia symptoms.
Sulfonylureas or insulin: monitor for additive hypoglycaemia.

Frequently Asked Questions

Linagliptina/Metformina Stada is a prescription oral medication used to improve blood glucose control in adults with type 2 diabetes mellitus, typically when diet, exercise, and monotherapy are insufficient.

Linagliptin blocks the enzyme dipeptidyl peptidase‑4 (DPP‑4), which increases the levels of incretin hormones. This enhances glucose‑dependent insulin secretion and reduces glucagon release, helping lower blood sugar after meals.

The specific dose and dosing schedule are determined by the prescribing healthcare professional based on the patient’s clinical condition, renal function, and response to therapy. Patients should follow the prescriber’s instructions exactly.

Safety in pregnancy and lactation has not been fully established. The medication should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified clinician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptina/Metformina combines a DPP‑4 inhibitor with metformin, offering dual mechanisms of action. Compared with metformin alone, it provides additional post‑prandial glucose control, and unlike sulfonylureas, it carries a lower risk of hypoglycaemia when used as monotherapy.

The tablets should be stored at room temperature, below 25 °C, in the original blister pack or container, protected from moisture and direct sunlight to maintain stability.

The medication is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not crushed or chewed.

Serious risks include lactic acidosis (especially in patients with renal impairment), pancreatitis, severe allergic reactions, and acute kidney injury. Patients should be educated to seek immediate medical attention if they experience unexplained abdominal pain, rapid breathing, or signs of severe hypersensitivity.

The drug is contraindicated in patients with severe renal impairment (eGFR <30 mL/min/1.73 m²), known hypersensitivity to either component, and in those with a history of lactic acidosis. Caution is also advised for individuals with significant hepatic disease.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.